Research & Literature

New Classification Criteria for Systemic Sclerosis (Scleroderma).

Pope JE, Johnson SR

Rheumatic diseases clinics of North America 2015; (41(3)):383-98.

Limited joint mobility syndrome in diabetes mellitus: A minireview.

Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ

World journal of diabetes 2015; (6(9)):1108-12 doi:10.4239/wjd.v6.i9.1108.

Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.

Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, et al.

The Journal of rheumatology 2015; (42(12)):2327-31 doi:10.3899/jrheum.150144.

Assessment of Central Corneal Thickness in Different Subtypes of Systemic Sclerosis.

Gomes BA, Santhiago MR, Kara-Junior N, et al.

Ocular immunology and inflammation 2016; (24(6)):693-698 doi:10.3109/09273948.2015.1076008.

Caring for the Patient With Limited Systemic Scleroderma.

Lachner KD

Orthopedic nursing 2016; (35(1)):5-10; quiz 11-2 doi:10.1097/NOR.0000000000000212.

Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.

Vandecasteele E, De Pauw M, De Keyser F, et al.

International journal of cardiology 2016; (212()):265-73.

Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic.

Melchor S, Joven BE, Andreu JL, et al.

Seminars in arthritis and rheumatism 2016; (46(3)):350-355 doi:10.1016/j.semarthrit.2016.05.007.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, et al.

Annals of the rheumatic diseases 2017; (76(8)):1327-1339 doi:10.1136/annrheumdis-2016-209909.

Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.

Manetti M, Romano E, Rosa I, et al.

Annals of the rheumatic diseases 2017; (76(5)):924-934 doi:10.1136/annrheumdis-2016-210229.

Pseudohypertension-Like Presentation: An Exceptionally Rare Presentation in an Athletic Female Patient with Morphea.

Al-Imam A

Case reports in dermatological medicine 2016; (2016()):7027352 doi:10.1155/2016/7027352.

Pulmonary hypertension in connective tissue diseases: an update.

Aithala R, Alex AG, Danda D

International journal of rheumatic diseases 2017; (20(1)):5-24 doi:10.1111/1756-185X.13001.

Morphea and Eosinophilic Fasciitis: An Update.

Mertens JS, Seyger MMB, Thurlings RM, et al.

American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.

Scleroderma-like Disorders.

Sharma A

Current rheumatology reviews 2018; (14(1)):22-27 doi:10.2174/1573397113666170612091419.

Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study.

Wangkaew S, Lertthanaphok S, Puntana S, Noppakun K

International journal of rheumatic diseases 2017; (20(10)):1562-1571 doi:10.1111/1756-185X.13145.

Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

Araújo FC, Camargo CZ, Kayser C

Rheumatology international 2017; (37(11)):1825-1833 doi:10.1007/s00296-017-3787-1.

Cardio-pulmonary involvement in systemic sclerosis: A study at a tertiary care center.

Arakkal G, Chintagunta SR, Chandika V, et al.

Indian journal of dermatology, venereology and leprology 2017; (83(6)):677-682 doi:10.4103/0378-6323.198453.

Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study.

Hesselvig JH, Kofoed K, Wu JJ, et al.

Acta dermato-venereologica 2018; (98(3)):361-365 doi:10.2340/00015555-2842.

[Renal Involvement in Connective Tissue Diseases].

Weiner SM

Deutsche medizinische Wochenschrift (1946) 2018; (143(2)):89-100 doi:10.1055/s-0043-106563.

Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis.

Gordon SM, Stitt RS, Nee R, et al.

The Journal of rheumatology 2019; (46(1)):85-92 doi:10.3899/jrheum.171186.

Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.

Tartar DM, Chung L, Fiorentino DF

Clinics in dermatology 2018; (36(4)):508-524 doi:10.1016/j.clindermatol.2018.04.008.

EndMT: A promising and controversial field.

Hong L, Du X, Li W, et al.

European journal of cell biology 2018; (97(7)):493-500 doi:10.1016/j.ejcb.2018.07.005.

ANCA-Associated Vasculitis Co-Occurrence With Systemic Sclerosis: A Case Report of a Rare Diagnostic Dilemma.

Cheta J, Binder M, Kowalewska J, Magoon S

Journal of investigative medicine high impact case reports 2018; (6()):2324709618785188 doi:10.1177/2324709618785188.

[Mimetics of systemic sclerosis].

Jendrek ST, Kahle B, Riemekasten G

Zeitschrift fur Rheumatologie 2019; (78(1)):14-23 doi:10.1007/s00393-018-0538-y.

Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.

Hu S, Hou Y, Wang Q, et al.

Arthritis research & therapy 2018; (20(1)):235 doi:10.1186/s13075-018-1735-4.

B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis.

Nešković JS, Ristić A, Petronijević M, et al.

Journal of medical biochemistry 2018; (37(4)):406-414 doi:10.1515/jomb-2017-0058.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, et al.

Arthritis research & therapy 2019; (21(1)):23 doi:10.1186/s13075-019-1809-y.

Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy.

Kayser C, Bredemeier M, Caleiro MT, et al.

Advances in rheumatology (London, England) 2019; (59(1)):5 doi:10.1186/s42358-018-0046-4.

The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality.

Horsley-Silva JL, Umar SB, Vela MF, et al.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2019; (32(5)) doi:10.1093/dote/doy136.

Eosinophilic fasciitis: From pathophysiology to treatment.

Ihn H

Allergology international : official journal of the Japanese Society of Allergology 2019; (68(4)):437-439 doi:10.1016/j.alit.2019.03.001.

Correlations between nailfold microvascular damage and skin involvement in systemic sclerosis patients.

Ruaro B, Pizzorni C, Paolino S, et al.

Microvascular research 2019; (125()):103874 doi:10.1016/j.mvr.2019.04.004.

Translational optical coherence elastography for assessment of systemic sclerosis.

Liu CH, Assassi S, Theodore S, et al.

Journal of biophotonics 2019; (12(12)):e201900236 doi:10.1002/jbio.201900236.

Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features.

Corallo C, Fioravanti A, Tenti S, et al.

Rheumatology international 2019; (39(10)):1767-1775 doi:10.1007/s00296-019-04401-w.

Diffused Alveolar Hemorrhage in the Setting of Scleroderma Renal Crisis.

Henao J, Fernandez R, Tejada Arias K, Chae C

Cureus 2019; (11(6)):e4932 doi:10.7759/cureus.4932.

Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

Shanmugam VK, Frech TM, Steen VD, et al.

Clinical rheumatology 2020; (39(1)):93-102 doi:10.1007/s10067-019-04792-y.

Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.

Noviani M, Saffari SE, Tan JL, et al.

Seminars in arthritis and rheumatism 2020; (50(3)):473-479 doi:10.1016/j.semarthrit.2019.11.005.

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.

Fischer A, Patel NM, Volkmann ER

Open access rheumatology : research and reviews 2019; (11()):283-307 doi:10.2147/OARRR.S226695.

Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.

Iniesta Arandia N, Espinosa G, Tolosa Vilella C, et al.

Clinical and experimental rheumatology 2020; (38 Suppl 125(3)):106-114.

Morphea: a practical review of its diagnosis, classification and treatment.

Rodríguez-Salgado P, García-Romero MT

Gaceta medica de Mexico 2019; (155(5)):483-491 doi:10.24875/GMM.M20000336.

Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis.

Repa A, Avgoustidis N, Kougkas N, et al.

Mediterranean journal of rheumatology 2019; (30(1)):48-50 doi:10.31138/mjr.30.1.48.

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

Bütikofer L, Varisco PA, Distler O, et al.

Arthritis research & therapy 2020; (22(1)):59 doi:10.1186/s13075-020-2141-2.

Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.

Utsunomiya A, Hasegawa M, Oyama N, et al.

Modern rheumatology 2021; (31(1)):162-170 doi:10.1080/14397595.2020.1751408.

Update on Management of Morphea (Localized Scleroderma) in Children.

George R, George A, Kumar TS

Indian dermatology online journal 2020; (11(2)):135-145 doi:10.4103/idoj.IDOJ_284_19.

Sclerodermalike syndromes: Great imitators.

Varjú C, Kumánovics G, Czirják L, et al.

Clinics in dermatology 2020; (38(2)):235-249 doi:10.1016/j.clindermatol.2019.10.010.

Renal Involvement in Systemic Sclerosis: An Update.

Chrabaszcz M, Małyszko J, Sikora M, et al.

Kidney & blood pressure research 2020; (45(4)):532-548 doi:10.1159/000507886.

A Case of Extensive Debilitating Generalized Morphea.

Sapra A, Dix R, Bhandari P, et al.

Cureus 2020; (12(5)):e8117 doi:10.7759/cureus.8117.

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis.

Bernstein EJ, Jaafar S, Assassi S, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(11)):1892-1896 doi:10.1002/art.41415.

Reduced ventilatory efficiency during exercise predicts major vascular complications and mortality for interstitial lung disease in systemic sclerosis.

Rosato E, Leodori G, Gigante A, et al.

Clinical and experimental rheumatology 2020; (38 Suppl 125(3)):85-91.

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Khanna D, Lin CJF, Furst DE, et al.

The Lancet. Respiratory medicine 2020; (8(10)):963-974 doi:10.1016/S2213-2600(20)30318-0.

Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma.

Pasumarthi A, Mago S, Banerjee P, Tadros M

Cureus 2020; (12(11)):e11553 doi:10.7759/cureus.11553.

Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Zhao M, Wu J, Wu H, et al.

Clinical reviews in allergy & immunology 2022; (62(2)):273-291 doi:10.1007/s12016-020-08831-4.

Autologous stem cell transplantation in scleroderma.

Farge D, Ait Abdallah N, Marjanovic Z, Del Papa N

Presse medicale (Paris, France : 1983) 2021; (50(1)):104065 doi:10.1016/j.lpm.2021.104065.

Scleroderma renal crisis.

Hudson M, Ghossein C, Steen V

Presse medicale (Paris, France : 1983) 2021; (50(1)):104063 doi:10.1016/j.lpm.2021.104063.

Recurrent Plaque Morphea Successfully Treated with PDO Mono Threads and Topical Tacrolimus Ointment.

Sakhiya J, Sakhiya D, Dedakiya A, et al.

The Journal of clinical and aesthetic dermatology 2020; (13(10)):38-41.

Nailfold capillaroscopy in systemic diseases: short overview for internal medicine.

Dima A, Berza I, Popescu DN, Parvu MI

Romanian journal of internal medicine = Revue roumaine de medecine interne 2021; (59(3)):201-217 doi:10.2478/rjim-2021-0007.

Treatment for systemic sclerosis-associated interstitial lung disease.

Roofeh D, Lescoat A, Khanna D

Current opinion in rheumatology 2021; (33(3)):240-248 doi:10.1097/BOR.0000000000000795.

Systemic Sclerosis and Pulmonary Disease.

Ngo K

Advances in experimental medicine and biology 2021; (1303()):173-182 doi:10.1007/978-3-030-63046-1_10.

Systemic sclerosis (scleroderma): remaining challenges.

Connolly MK

Annals of translational medicine 2021; (9(5)):438 doi:10.21037/atm-20-5449.

New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Lescoat A, Varga J, Matucci-Cerinic M, Khanna D

Expert opinion on investigational drugs 2021; (30(6)):635-652 doi:10.1080/13543784.2021.1923693.

The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Ruaro B, Confalonieri M, Salton F, et al.

Pharmaceuticals (Basel, Switzerland) 2021; (14(5)) doi:10.3390/ph14050403.

Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment.

Sundblad V, Gomez RA, Stupirski JC, et al.

Frontiers in pharmacology 2021; (12()):650605 doi:10.3389/fphar.2021.650605.

A mixed method study exploring patient satisfaction and feasibility of two exercise programmes in systemic sclerosis-associated microstomia.

Sydow E, Van der Elst K, Verschueren P, et al.

Rheumatology advances in practice 2021; (5(2)):rkab017 doi:10.1093/rap/rkab017.

The Efficacy of a Home-Based, Self-Administered Hand Exercise Program for Patients With Systemic Sclerosis: A Randomized Controlled, Evaluator-Blind, Clinical Trial.

Gokcen N, Badak SO, Sarpel T, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):e422-e429 doi:10.1097/RHU.0000000000001752.

Emerging treatments for scleroderma/systemic sclerosis.

Zhu JL, Black SM, Chen HW, Jacobe HT

Faculty reviews 2021; (10()):43 doi:10.12703/r/10-43.

New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.

Romano E, Rosa I, Fioretto BS, et al.

Life (Basel, Switzerland) 2021; (11(7)) doi:10.3390/life11070610.

Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

Herrick AL, Griffiths-Jones DJ, Ryder WD, et al.

Journal of scleroderma and related disorders 2021; (6(2)):146-153 doi:10.1177/2397198320957552.

Upcoming treatments for morphea.

Wenzel D, Haddadi NS, Afshari K, et al.

Immunity, inflammation and disease 2021; (9(4)):1101-1145 doi:10.1002/iid3.475.

Esophageal manifestation in patients with scleroderma.

Voulgaris TA, Karamanolis GP

World journal of clinical cases 2021; (9(20)):5408-5419 doi:10.12998/wjcc.v9.i20.5408.

Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

Lescoat A, Murphy SL, Roofeh D, et al.

Journal of scleroderma and related disorders 2021; (6(1)):66-76 doi:10.1177/2397198320961967.

Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

Lescoat A, Roofeh D, Kuwana M, et al.

Clinical reviews in allergy & immunology 2023; (64(3)):239-261 doi:10.1007/s12016-021-08891-0.

Regulation of Partial and Reversible Endothelial-to-Mesenchymal Transition in Angiogenesis.

Fang JS, Hultgren NW, Hughes CCW

Frontiers in cell and developmental biology 2021; (9()):702021 doi:10.3389/fcell.2021.702021.

High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients.

Ruaro B, Baratella E, Confalonieri P, et al.

Diagnostics (Basel, Switzerland) 2021; (11(11)) doi:10.3390/diagnostics11111960.

Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.

Yang L, Sun W, Yao Q

The Journal of international medical research 2021; (49(11)):3000605211060160 doi:10.1177/03000605211060160.

Clinical features and prognostic factors of systemic sclerosis in Guangxi, China: Retrospective, single-center study of long-term survival in 470 patients.

Chen J, Yang C, Pan J, et al.

International journal of rheumatic diseases 2022; (25(2)):182-191 doi:10.1111/1756-185X.14261.

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.

Chung L, Spino C, McLain R, et al.

The Lancet. Rheumatology 2020; (2(12)):e743-e753 doi:10.1016/S2665-9913(20)30237-X.

NADPH-derived ROS generation drives fibrosis and endothelial-to-mesenchymal transition in systemic sclerosis: Potential cross talk with circulating miRNAs.

Posadino AM, Erre GL, Cossu A, et al.

Biomolecular concepts 2022; (13(1)):11-24 doi:10.1515/bmc-2021-0023.

Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.

Chong WH, Saha BK, Beegle S

The American journal of the medical sciences 2023; (365(2)):198-204 doi:10.1016/j.amjms.2022.01.023.

Antinuclear antibody pattern and autoantibody profiling of systemic sclerosis patients in a tertiary referral center in North India.

Machhua S, Sharma SK, Kumar Y, et al.

Pathology international 2022; (72(5)):283-292 doi:10.1111/pin.13221.

Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen.

Lazzaroni MG, Airò P

Journal of scleroderma and related disorders 2018; (3(3)):214-220 doi:10.1177/2397198318786158.

Patient perception of disease burden in diffuse cutaneous systemic sclerosis.

Khanna D, Allanore Y, Denton CP, et al.

Journal of scleroderma and related disorders 2020; (5(1)):66-76 doi:10.1177/2397198319866615.

Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.

Showalter K, Merkel PA, Khanna D, Gordon JK

Journal of scleroderma and related disorders 2020; (5(3)):167-171 doi:10.1177/2397198320921044.

High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.

Furtado S, Dunogué B, Jourdi G, et al.

Journal of scleroderma and related disorders 2021; (6(2)):178-186 doi:10.1177/2397198320957558.

Immunosuppression use in early systemic sclerosis may be increasing over time.

Park R, Nevskaya T, Baron M, Pope JE

Journal of scleroderma and related disorders 2022; (7(1)):33-41 doi:10.1177/23971983211000971.

Nailfold capillaroscopy for the early diagnosis of the scleroderma spectrum of diseases in patients without Raynaud's phenomenon.

Hong C, Xiang L, Saffari SE, Low AH

Journal of scleroderma and related disorders 2022; (7(2)):144-150 doi:10.1177/23971983221088460.

Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes.

Tieu A, Chaigne B, Dunogué B, et al.

Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051067.

Systemic Sclerosis, Malnutrition, and Small Bowel Obstruction: Why Clinicians Should Consider Early Total Parenteral Nutrition in Systemic Sclerosis With Severe Gastrointestinal Involvement.

Massat B, McCarthy J

Cureus 2022; (14(8)):e27638 doi:10.7759/cureus.27638.

Insights into molecular and clinical characteristics of very early systemic sclerosis.

Bellando-Randone S, Del Galdo F, Matucci-Cerinic M

Current opinion in rheumatology 2022; (34(6)):351-356 doi:10.1097/BOR.0000000000000903.

Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.

Malewska-Woźniak A, Osmola-Mañkowska A, Adamski Z

Postepy dermatologii i alergologii 2022; (39(4)):757-761 doi:10.5114/ada.2021.108437.

Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.

Nagy T, Toth NM, Palmer E, et al.

Biomedicines 2022; (10(9)) doi:10.3390/biomedicines10092129.

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.

Khanna D, Distler O, Cottin V, et al.

Journal of scleroderma and related disorders 2022; (7(3)):168-178 doi:10.1177/23971983211064463.

Gastrointestinal involvement in systemic sclerosis: An updated review.

Nassar M, Ghernautan V, Nso N, et al.

Medicine 2022; (101(45)):e31780 doi:10.1097/MD.0000000000031780.

The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.

Silva C, Solanki KK, White DHN

Rheumatology and immunology research 2022; (3(2)):84-89 doi:10.2478/rir-2022-0014.

Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.

Kreuter M, Bonella F, Blank N, et al.

Rheumatology (Oxford, England) 2023; (62(9)):3067-3074 doi:10.1093/rheumatology/kead023.

Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.

Poonia K, Bhalla M, Dogar K, et al.

Clinical rheumatology 2023; (42(7)):1827-1832 doi:10.1007/s10067-023-06562-3.

Very Early Diagnosis of Systemic Sclerosis in Clinical Practice - Case Report and Review of the Literature.

Marković I, Posavec AL, Morović-Vergles J, Mitrović J

Acta dermatovenerologica Croatica : ADC 2022; (30(4)):251-255.

Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives.

Stubbs LA, Ferry AM, Guffey D, et al.

Pediatric rheumatology online journal 2023; (21(1)):39 doi:10.1186/s12969-023-00819-6.

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France.

Nicolas A, Leroy S, Mouthon L, et al.

Therapeutic advances in musculoskeletal disease 2023; (15()):1759720X231159712 doi:10.1177/1759720X231159712.

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.

Maciejewska M, Stec A, Zaremba M, et al.

Clinical, cosmetic and investigational dermatology 2023; (16()):1351-1361 doi:10.2147/CCID.S409490.

Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

Namas R, Elarabi M, Khan S, et al.

Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.

Dave J, Mahajan S, Khadilkar P, Pradhan V

The Journal of the Association of Physicians of India 2022; (70(11)):11-12 doi:10.5005/japi-11001-0136.

Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).

Bağlan E, Kızıldağ Z, Çağlayan Ş, et al.

Clinical rheumatology 2023; (42(10)):2855-2860 doi:10.1007/s10067-023-06677-7.

Immunologic and nonimmunologic sclerodermal skin conditions - review.

Bobeica C, Niculet E, Craescu M, et al.

Frontiers in immunology 2023; (14()):1180221 doi:10.3389/fimmu.2023.1180221.

Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?

Campochiaro C, Allanore Y, Braun-Moscovici Y, et al.

Autoimmunity reviews 2024; (23(1)):103439 doi:10.1016/j.autrev.2023.103439.

Impact of the COVID-19 Pandemic on Health Care Access and Diagnosis of Pulmonary Arterial Hypertension Among Patients With Systemic Sclerosis.

Callisto A, Hansen D, Walker J, et al.

Arthritis care & research 2024; (76(1)):81-87 doi:10.1002/acr.25239.

The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease.

Martín-López M, Carreira PE

Journal of clinical medicine 2023; (12(20)) doi:10.3390/jcm12206680.

Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease.

Hughes M, Allanore Y, Baron M, et al.

The Lancet. Rheumatology 2022; (4(11)):e795-e803 doi:10.1016/S2665-9913(22)00183-7.

Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.

Philip SS, Janardana R, Shenoy P, et al.

Journal of scleroderma and related disorders 2024; (9(1)):29-37 doi:10.1177/23971983231215470.

[Localized scleroderma].

Al-Gburi S, Kreuter A, Moinzadeh P

Dermatologie (Heidelberg, Germany) 2024; (75(3)):197-207 doi:10.1007/s00105-024-05297-9.

Understanding diabetic cheiroarthropathy: a focus on clinical presentation.

Persad-Paisley EM, Lee C, Bhatt RA

Journal of surgical case reports 2024; (2024(3)):rjae123 doi:10.1093/jscr/rjae123.

Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation.

May CK, Noble PW, Herzog EL, et al.

Biochemical and biophysical research communications 2024; (720()):150123 doi:10.1016/j.bbrc.2024.150123.

Interferon-γ Induces Interleukin-6 Production and Alpha-smooth Muscle Actin Expression in Systemic Sclerosis Fibroblasts.

Rokni M, Farhadi E, Kavosi H, et al.

Iranian journal of allergy, asthma, and immunology 2024; (23(2)):197-220 doi:10.18502/ijaai.v23i2.15325.

Diabetic cheiroarthropathy in uncontrolled type 2 diabetes with positive anti-nuclear antibodies: a case report from Sudan.

Abdalla E, Gamar AM, Taha ZI, Alfatih M

Annals of medicine and surgery (2012) 2024; (86(6)):3631-3635 doi:10.1097/MS9.0000000000001993.

Assessing hand and global disability in a cohort of Algerian patients with systemic sclerosis: Construct validities of the Arab Hand Function Index and the Arabic Health Assessment Questionnaire.

Benmostefa N, Malek R, Robert M, et al.

Journal of scleroderma and related disorders 2024; (9(2)):134-142 doi:10.1177/23971983241231082.

Approach to interstitial lung disease associated with systemic sclerosis-A survey to pulmonologists and rheumatologists in Colombia.

Galindo JL, García OM, Gil DR, et al.

Reumatologia clinica 2024; (20(6)):334-340 doi:10.1016/j.reumae.2023.12.010.

The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study.

Virgili-Gervais G, Matthews B, Nassar EL, et al.

The Lancet. Rheumatology 2024; (6(10)):e684-e692 doi:10.1016/S2665-9913(24)00189-9.

Kidney Transplantation in a Patient with Scleroderma.

Bear L, Agmon Levine N, Ghinea R, et al.

The Israel Medical Association journal : IMAJ 2024; (26(9)):593-595.

Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?

Bautista-Sanchez R, Khanna D

Rheumatology and immunology research 2024; (5(3)):157-165 doi:10.2478/rir-2024-0022.

Clinical signs and utility of CT PET scan in eosinophilic fasciitis?

Adamson SR, Su JC, Ng S, Fong C

Skin health and disease 2024; (4(6)):e439 doi:10.1002/ski2.439.

Linear Scleroderma En Coup de Sabre: A Case Series With Eyelid Involvement and Management.

Kok LT, Malik M, Fayers T, et al.

Ophthalmic plastic and reconstructive surgery 2025; (41(3)):e80-e85 doi:10.1097/IOP.0000000000002843.

Digital Ulcers and Microvascular Abnormalities Presenting As the Initial Manifestations of Pre-scleroderma.

Arango A, Yaman RN, Mumtaz S, et al.

Cureus 2024; (16(12)):e75061 doi:10.7759/cureus.75061.

Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.

Hinchcliff M, Khanna D, De Lorenzis E, et al.

The Lancet. Rheumatology 2025; (7(6)):e403-e414 doi:10.1016/S2665-9913(24)00403-X.

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Hanif I, Assassi S, Mayes MD, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(11)):1585-1595 doi:10.1002/art.43237.

Frequency and determinants of use of immunosuppressants in the Australian Scleroderma Cohort Study.

Fairley JL, Hansen D, Proudman S, et al.

Journal of scleroderma and related disorders 2025; 23971983251342690 doi:10.1177/23971983251342690.

The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.

Al Oweidat KS, Abdulelah AA, Toubasi AA, et al.

Canadian respiratory journal 2025; (2025()):1682546 doi:10.1155/carj/1682546.

Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis.

Elhannani A, Martel ME, Collet A, et al.

Rheumatology (Oxford, England) 2025; (64(12)):6023-6035 doi:10.1093/rheumatology/keaf392.

What have we learned about systemic sclerosis from the EUSTAR database?

Campochiaro C, Vonk MC, Osborne T, et al.

Current opinion in rheumatology 2026; (38(1)):53-59 doi:10.1097/BOR.0000000000001128.

Evaluation of malignancy risk in patients with SSc by autoantibody profile: a systematic review with meta-analysis.

Towachiraporn K, Sanyanusin W, Rojhirunsakool S, et al.

Rheumatology advances in practice 2025; (9(4)):rkaf115 doi:10.1093/rap/rkaf115.

Raynaud's Phenomenon and Pericardial Effusion Requiring Management with A Pericardial Window as the only Manifestations of Systemic Sclerosis without Scleroderma for over 10 Years, after which Pulmonary Hypertension Developed.

Moriarty N, Vadiveloo TDV, Osman F, et al.

European journal of case reports in internal medicine 2025; (12(11)):005866 doi:10.12890/2025_005866.

[En coup de sabre linear scleroderma with central nervous system involvement in a pediatric patient].

Kulikova SL, Semashko MD, Levshuk ON, et al.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2025; (125(10. Vyp. 2)):120-126 doi:10.17116/jnevro2025125102120.

Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling.

Jarnagin HC, Parvizi R, Gong Z, et al.

JCI insight 2026; (11(3)).

Prevalence and severity of complicated Raynaud's phenomenon in limited and diffuse systemic sclerosis: a multicenter study in Iraq.

Jaafar F, Moayad Z, Gorial F, Alkazzaz A

Reumatologia 2025; (63(6)):383-388 doi:10.5114/reum/207625.